Expression Profiles And Prognostic Implications Of Clinically Actionable Tumor-Associated Antigens Across Diverse Clinicopathological Subtypes of Prostate Cancer: a Bidirectional Cohort Study

1. Study Type This is a single-center, observational cohort study incorporating both retrospective and prospective components. It is a non-interventional study that does not involve assignment of participants to specific interventions.
2. Objectives

Primary Objectives:

1. To determine the protein expression profile (positive rate, expression level) of 15 membrane targets (PSMA, B7-H3, STEAP1, TROP2, KLK2, HER2, TF, HER3, DLL3, SEZ6, STEAP2, MUC1, NECTIN4, FAP, PDL1) in diverse clinicopathological subtypes of prostate cancer (HSPC and CRPC，primary and metastatic lesions include lymph node, bone and visceral metastasis, etc.).
2. To characterize the molecular subtypes of prostate cancer based on the expression profiles of AR, PSA, PSMA, Syn, CgA, CD56, p53, RB1, and PTEN across different disease states and metastatic sites.
3. To validate the association between the expression of prognostically significant targets (identified in the retrospective cohort) and overall survival (OS) in an independent, prospectively enrolled cohort of prostate cancer patients.

Secondary Objectives:

1. To compare the expression of each target between matched CSPC and mCRPC samples from the same patients.
2. To compare the expression of each target across different metastatic sites (e.g., bone, lymph node, viscera) in mCRPC.
3. To analyze the association between target expression and clinical outcomes [biochemical recurrence-free survival (BFS), metastasis-free survival (MFS)] in patients with CSPC.
4. To explore co-expression patterns of the targets and their correlation with clinicopathological features.